Kronos Bio Stock

kronosbio.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $123MM

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

Register To Buy and Sell Shares

For more details on financing and valuation for Kronos Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Kronos Bio’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Kronos Bio.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Philip Gutry
Chief Business Officer
Jorge Dimartino Ph.D
Chief Medical Officer & Executive Vice President
Christopher Wilfong
Chief Operating Officer & Co-Founder
Angela Koehler Ph.D
Scientific Founder
Norbert Bischofberger Ph.D
Chief Executive Officer, President & Board Member

Board Members

Arie Belldegrun MD
Vida Ventures (Boston)
John Martin Ph.D
Rebecka Belldegrun MD
Bellco Capital
Joshua Kazam
Two River Group
David Tanen
Two River Group
Otello Stampacchia Ph.D
Omega Fund
Norbert Bischofberger Ph.D
Jakob Loven Ph.D
Nextech Invest

News Highlights

Xconomy: Kronos Bio Reels In $105M for Drugs That Hit “Undruggable” Targets
Kronos Bio has raised $105 million in financing to develop therapies intended to target disease-causing proteins that have so far eluded the best efforts
Updated on: Dec 1, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.